Inactive Instrument

Highlights DICE THER

Equities

DICE

US23345J1043

Highlights

Unlock all the news: Be the first to know and act before the market!

Eli Lilly Completes Acquisition of DICE Therapeutics	23-08-09	MT
Eli Lilly Wraps Up Acquisition of Dice Therapeutics	23-08-09	MT
Eli Lilly and Company completed the acquisition of DICE Therapeutics, Inc. from a group of shareholders.	23-08-08	CI
DICE Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08	CI
Eli Lilly Extends Tender Offer to Acquire DICE Therapeutics to Aug. 9	23-07-25	MT
Eli Lilly Extends $2.4 Billion Tender Offer to Buy DICE Therapeutics	23-07-25	MT
MoonLake Immunotherapeutics explores sale-sources	23-07-14	RE
Eli Lilly to Acquire Dice Therapeutics for $2.4 Billion in Cash; Dice Shares Jump	23-06-20	MT
Eli Lilly Signs $2.4 Billion Deal to Buy Dice Therapeutics	23-06-20	MT
Fed Remarks, China Rate Cut Leave Exchange-Traded Funds, Equity Futures Lower Premarket Tuesday	23-06-20	MT
Eli Lilly to Acquire Dice Therapeutics for $2.4 Billion in Cash	23-06-20	MT
Eli Lilly to Acquire DICE Therapeutics for $2.4 Billion	23-06-20	DJ
Eli Lilly to Buy US-based DICE Therapeutics in $2.4 Billion Tender Offer Deal	23-06-20	MT
Eli Lilly to buy Dice Therapeutics in $2.4 billion deal	23-06-20	RE
Eli Lilly and Company entered into a definitive agreement to acquire DICE Therapeutics, Inc. from RA Capital Healthcare Fund, L.P. and RA Capital Healthcare Fund, L.P., funds managed by RA Capital Management, L.P., J. Kevin Judice and others for $2.3 billion.	23-06-19	CI
DICE Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Earnings Flash (DICE) DICE THERAPEUTICS Reports Q3 Loss $-0.55	22-11-09	MT
DICE Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-09	CI
ETF Preview: ETFs, Futures Lower Premarket After Small Business Optimism Data	22-10-11	MT
DICE Therapeutics, Inc. Announces Positive Topline Data from Phase 1 Clinical Trial of Lead Oral IL-17 Antagonist, DC-806, for Psoriasis	22-10-11	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights DICE THER

Equities

DICE

US23345J1043

Highlights

Filters